Literature DB >> 29502292

Whole-Genome Expression Microarray Combined with Machine Learning to Identify Prognostic Biomarkers for High-Grade Glioma.

Chang Shu1, Qiong Wang2, Xiaoling Yan2, Jinhuan Wang3,4.   

Abstract

The aim of our study is to build a framework for a better understanding of high-grade glioma (HGG) prognostic-related biomarkers. Whole-genome gene expression microarray was performed to identify differently expressed genes between HGGs and low-grade diffuse gliomas. Several machine learning algorithms were used to filter prognostic-related genes. One hundred ninety-three HGG patients after surgical resection were selected for survival analysis. Immunohistochemistry were performed on these tumor samples to analyze IDH1 mutation status and protein expression of WEE1. qRT-PCR, western blotting, transwell assays, and scratch wound healing assays were performed to evaluate the effect of WEE1 knockdown or overexpression in HGG cells. Three prognostic-related genes (WEE1, IGF2PB3, and EMP3) were demonstrated to separate HGG patients into two different survival subgroups. The area under receiver operating characteristic curve of WEE1 was higher than that of IGF2BP3, EMP3, age, IDH status, 1p/19q status, and MGMT promoter status. WEE1 was an independent covariate compared with IDH status, age, and WHO grade. Knockdown or overexpression of WEE1 can inhibit or promote migration and invasion in U251 and U87 cell lines. WEE1, EMP3, and IGF2BP3 are reliable prognostic-related genes at the mRNA level. WEE1 is an independent prognostic biomarker in survival analysis and has potential diagnostic value for HGG patients. WEE1 can induce HGG cell migration and invasion in vitro.

Entities:  

Keywords:  EMP3; High-grade glioma; IGF2BP3; Microarray; WEE1

Mesh:

Substances:

Year:  2018        PMID: 29502292     DOI: 10.1007/s12031-018-1049-7

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  29 in total

1.  WEE1 Kinase As a Target for Cancer Therapy.

Authors:  Sabine Mueller; Daphne A Haas-Kogan
Journal:  J Clin Oncol       Date:  2015-07-27       Impact factor: 44.544

2.  Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog.

Authors:  P Russell; P Nurse
Journal:  Cell       Date:  1987-05-22       Impact factor: 41.582

3.  Molecular Pathology of Patient Tumors, Patient-Derived Xenografts, and Cancer Cell Lines.

Authors:  Sheng Guo; Wubin Qian; Jie Cai; Likun Zhang; Jean-Pierre Wery; Qi-Xiang Li
Journal:  Cancer Res       Date:  2016-06-20       Impact factor: 12.701

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

Authors:  Khanh Do; Deborah Wilsker; Jiuping Ji; Jennifer Zlott; Tomoko Freshwater; Robert J Kinders; Jerry Collins; Alice P Chen; James H Doroshow; Shivaani Kummar
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

Review 6.  Understanding high grade glioma: molecular mechanism, therapy and comprehensive management.

Authors:  Yongzhi Wang; Tao Jiang
Journal:  Cancer Lett       Date:  2013-01-20       Impact factor: 8.679

7.  Comparison of Cox and Gray's survival models in severe sepsis.

Authors:  Jan Kasal; Zorana Jovanovic; Gilles Clermont; Lisa A Weissfeld; Vladimir Kaplan; R Scott Watson; Derek C Angus
Journal:  Crit Care Med       Date:  2004-03       Impact factor: 7.598

8.  Targeting Wee1 for the treatment of pediatric high-grade gliomas.

Authors:  Sabine Mueller; Rintaro Hashizume; Xiaodong Yang; Ilan Kolkowitz; Aleksandra K Olow; Joanna Phillips; Ivan Smirnov; Maxwell W Tom; Michael D Prados; C David James; Mitchel S Berger; Nalin Gupta; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

9.  High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma.

Authors:  Chunzhi Zhang; Junxia Zhang; Jianwei Hao; Zhendong Shi; Yingyi Wang; Lei Han; Shizhu Yu; Yongping You; Tao Jiang; Jinhuan Wang; Meili Liu; Peiyu Pu; Chunsheng Kang
Journal:  J Transl Med       Date:  2012-06-08       Impact factor: 5.531

10.  Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2.

Authors:  Ramaswamy Suvasini; Bhargava Shruti; Balaram Thota; Sridevi Vijay Shinde; Dinorah Friedmann-Morvinski; Zahid Nawaz; Krishnarao Venkatesh Prasanna; Kandavel Thennarasu; Alangar Sathyaranjandas Hegde; Arimappamagan Arivazhagan; Bangalore Ashwathnarayanarao Chandramouli; Vani Santosh; Kumaravel Somasundaram
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

View more
  4 in total

1.  Prognostic significance of age related genes in patients with lower grade glioma.

Authors:  Haiwei Wang; Xinrui Wang; Liangpu Xu; Ji Zhang; Hua Cao
Journal:  J Cancer       Date:  2020-04-06       Impact factor: 4.207

2.  GlioMarker: An integrated database for knowledge exploration of diagnostic biomarkers in gliomas.

Authors:  Zihan Ran; Jingcheng Yang; Yaqing Liu; XiuWen Chen; Zijing Ma; Shaobo Wu; Yechao Huang; Yueqiang Song; Yu Gu; Shuo Zhao; Mengqi Fa; Jiangjie Lu; Qingwang Chen; Zehui Cao; Xiaofei Li; Shanyue Sun; Tao Yang
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

Review 3.  Artificial intelligence for precision medicine in neurodevelopmental disorders.

Authors:  Mohammed Uddin; Yujiang Wang; Marc Woodbury-Smith
Journal:  NPJ Digit Med       Date:  2019-11-21

Review 4.  A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.

Authors:  Andrea Ghelli Luserna di Rorà; Claudio Cerchione; Giovanni Martinelli; Giorgia Simonetti
Journal:  J Hematol Oncol       Date:  2020-09-21       Impact factor: 17.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.